Spravato® (esketamine) for Depression Relief. Covered by insurance. Copays may be as little as $10 for eligible patients
Unlock healing with FDA-approved esketamine treatment.
Spravato® (esketamine) is a breakthrough nasal spray treatment for adults with treatment-resistant depression. While traditional antidepressants may take weeks or even months to show results, Spravato® often provides relief within hours. Patients begin to feel better sooner and regain the ability to fully engage in their lives. When other medications haven’t worked, Spravato® offers a meaningful, evidence-based option for relief. Reconnect with yourself—discover the difference Spravato® can make.
Our Process
1. Connect with Care
You may be referred to Ventana Mental Health for Spravato treatment by your psychiatrist, or reach out to us directly for a consultation to determine your eligibility.
Spravato is used to treat treatment resistant depression.
2. Meet Your Team
Visit with your psychiatrist virtually for initial appointment and treatment planning.
During this 1-hour session, you and your psychiatrist will discuss your history, current symptoms, and treatment options, including Spravato.
3. Focus on Healing
Spravato treatment typically involves twice weekly sessions for 4 weeks, then once weekly sessions for 4 weeks, then maintenance sessions determined by you and your team.
During each session, you’ll be receive spravato as a nasal spray.
Ventana Mental Health’s doctors and care team are present to support you before, during, and after treatment and help you integrate the experience.
The Science Behind Esketamine Treatment
Spravato® targets the glutamate system in the brain, which plays an important role in healthy brain functioning. Glutamate is a highly abundant neurotransmitter, responsible for facilitating signals between nerve cells. This process works with different pathways in the brain than traditionally prescribed medications, and often relief begins to be felt more quickly.
Image Source: https://www.nature.com/articles/nature17897
Research and understanding of this new approach for depression is continuing to deepen. It’s thought to create new connections in the brain, allowing for behavioral and cognitive changes to occur more readily and rapidly in patients with treatment-resistant depression. Clinical trials have shown over 60% response rate, and 52% remission rate in patients treated with Spravato® with minimal side effects.
Compliance & Safety Information
SPRAVATO® Program
SPRAVATO® (esketamine, CIII) is delivered only in our certified clinics under the SPRAVATO® REMS. After each dose, you’ll be monitored by a clinician for at least 2 hours before discharge. No at‑home use. See official safety information and Prescribing Information. Spravato Safety And Drug Information
Privacy
Your information is protected under our HIPAA Privacy Practices. Ventana Mental Health Privacy Policies
